Reported Earlier, Roche's Genentech Presents Long-Term Data at ASH 2024 Highlighting Durable Remissions With Fixed-Duration Columvi And Lunsumio
Reported Earlier, Roche's Genentech Presents Long-Term Data at ASH 2024 Highlighting Durable Remissions With Fixed-Duration Columvi And Lunsumio
– Long-term data confirm fixed-duration Columvi and Lunsumio achieve durable remissions beyond the end of treatment, with real-world data suggesting reduced treatment-related travel burden due to less frequent dosing –
– 长期数据显示，固定周期的Columvi和Lunsumio在治疗结束后仍能实现持久缓解，现实世界的数据表明，由于剂量减少，治疗相关的旅行负担减轻 –
– First presentation of Lunsumio given subcutaneously showed non-inferiority to intravenous treatment with a consistent safety profile, potentially providing an additional outpatient option with a shorter administration time –
– Lunsumio的首次皮下注射展示了与静脉治疗的非劣效性，并具有一贯的安全性，可能提供一种额外的门诊选择，具有更短的给药时间 –
– Positive results for Genentech's two bispecifics antibodies validate the company's efforts to provide multiple treatment options that suit the diverse needs of lymphoma patients and healthcare providers –
– Genentech的两种双特异性抗体的积极结果验证了该公司提供多种治疗选择的努力，以满足淋巴瘤患者和医疗服务提供者的不同需求 –
